Alexander Vos, VectorY CEO

Start­ing fresh in man­u­fac­tur­ing, For­bion start­up re­fu­els to steer next-gen gene ther­a­py ap­proach for ALS, Alzheimer's in­to clin­ic

For­bion laid out its case for a next-gen­er­a­tion gene ther­a­py ap­proach when it took the wraps off Vec­to­rY Ther­a­peu­tics and its vec­tor­ized an­ti­body tech in Feb­ru­ary. Now, the Dutch VC has tapped an ex­pe­ri­enced hand at cell and gene ther­a­py man­u­fac­tur­ing to steer the ship — and pulled a mar­quee syn­di­cate for a €31 mil­lion ($37.6 mil­lion) seed round.

Alexan­der Vos, the new CEO, is a ven­ture part­ner at Bio­Gen­er­a­tion Ven­tures and jumps im­me­di­ate­ly from Var­mX, a BGV port­fo­lio com­pa­ny de­vel­op­ing an an­ti­co­ag­u­lant. But be­fore that, he had led Dutch CD­MO Phar­ma­Cell for eight years un­til it was bought out by Lon­za.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.